Guide · 3 min read

Problematic polypharmacy and deprescribing: a guide for PCNs

When many medicines stop helping, the harm builds up. Here's how to find the patients most at risk and review their medicines properly.

Checked against the sources listed at the end on .

Clinically reviewed by Aisha Malik, Clinical Director (GPhC 2205843), on .

The short answer

Polypharmacy is the use of multiple medicines by one person. It's often right: the Specialist Pharmacy Service (SPS) calls polypharmacy appropriate when the medicines are clinically indicated, optimised and prescribed according to the best evidence. It becomes problematic when medicines are no longer suitable, the benefits no longer outweigh the harms, a combination causes or risks harm, or taking them has become unmanageable or distressing for the person.

Deprescribing is the answer to problematic polypharmacy. SPS defines it as tapering, stopping, discontinuing or withdrawing medicines that are no longer appropriate, beneficial or wanted. SPS links it to structured medication reviews and a person-centred approach, with decisions shared with the patient.

Why it matters

When the government published the national overprescribing review in September 2021, it said:

  • 10% of the prescription items dispensed through primary care in England are either inappropriate for the patient's circumstances and wishes, or could be better served with other treatments
  • 15% of people take five or more medicines a day
  • around 1 in 5 hospital admissions in people over 65, and around 6.5% of all hospital admissions, are caused by the adverse effects of medicines

SPS lists the harms linked to polypharmacy as adverse drug effects, medication errors, drug interactions, non-adherence, falls and frailty, cognitive impairment, hospital admissions and healthcare costs.

The gap is largest for people living with frailty. The National Audit Office reported that of the 226,000 people diagnosed with severe frailty in 2024-25, 16% had a medication review.

Which patients to prioritise

NHS England's Network Contract DES guidance asks primary care networks (PCNs) to use appropriate tools to find the patients who would benefit most from a structured medication review. It lists:

  • people in care homes
  • people with learning disabilities
  • people on 10 or more medicines
  • people on medicines commonly linked to medication errors and harm
  • people with severe frailty who are isolated or housebound, or who have recently been in hospital or had a fall
  • people using antidepressants, opioids, gabapentinoids, benzodiazepines or Z-drugs

NHSBSA's polypharmacy prescribing comparators, on ePACT2, help find them. They show practices and PCNs how many patients are on 8, 10, 15 or 20 or more medicines, and highlight combinations known to raise the risk of harm. The latest version adds patients on several analgesics at once, patients on an SSRI or SNRI with a medicine that raises bleeding risk, and patients on 2, 3, 4 or more medicines that can lower blood pressure.

Medicines and falls

NICE's falls guideline (NG249) covers people aged 65 or over, and people aged 50 to 64 with one or more factors that could raise their risk of falls. For people who need falls management in the community, it recommends considering a structured medication review to find any medicines that may increase their risk of falling, and considering adjusting them.

For people taking psychotropic medicines, NICE recommends reviewing those medicines, discussing the increased risk of falls with the person, and planning withdrawal as appropriate, liaising with specialist mental health services where needed.

What a good review covers

NICE defines a medication review as a structured, critical examination of a person's medicines, with the aim of reaching an agreement with them about treatment. NHS England's guidance says a structured medication review should look at:

  • Safety: benefit against risk, side effects, risks from other conditions, interactions and contraindications
  • Effectiveness: whether each medicine is indicated, recorded, working and wanted, and whether long-term conditions are controlled
  • Alternatives: whether the patient knows about alternatives, including social prescribing

Patients should be invited in a way that explains what the review is and that it's a shared decision. The clinician decides how many follow-ups are needed in partnership with the patient. NHS England's guidance gives SNOMED code 1239511000000100 for a structured medication review or a follow-up.

Where a clinical pharmacist helps

Deprescribing takes time: a long conversation with the patient, a plan for anything reduced gradually, and a follow-up to check how it went. A clinical pharmacist can:

  • build the review list from your practices' data and the NHSBSA comparators, in the order you agree
  • carry out structured medication reviews with patients and their carers
  • look first at medicines linked to falls, dependence and anticholinergic burden (see anticholinergic burden)
  • stop or reduce medicines safely, with a written plan and a follow-up date
  • flag anything that needs a GP's decision, with the evidence attached

Clinical pharmacists are one of the roles PCNs can fund through the Additional Roles Reimbursement Scheme (ARRS). We place remote clinical pharmacists with PCNs and GP practices, and every session is logged in ReportRx. See frailty reviews and structured medication reviews. This winter, a medication review can also be one part of a Proactive Care Plan for patients eligible for the Proactive Care Scheme.

Questions people ask

What is problematic polypharmacy?

The Specialist Pharmacy Service describes it as polypharmacy where medicines are no longer suitable, the benefits no longer outweigh the harms, a combination causes or risks harm, or taking them has become unmanageable or distressing for the person.

What is deprescribing?

Tapering, stopping, discontinuing or withdrawing medicines that are no longer appropriate, beneficial or wanted, as SPS defines it. SPS links it to structured medication reviews and a person-centred approach, with decisions shared with the patient.

Which patients should a PCN review first?

NHS England's DES guidance lists people in care homes, people with learning disabilities, people on 10 or more medicines, people on medicines commonly linked to errors and harm, people with severe frailty who are isolated, housebound or recently admitted or fallen, and people on antidepressants, opioids, gabapentinoids, benzodiazepines or Z-drugs.

How do medicines affect falls risk?

For people in the community who need falls management, NICE's falls guideline recommends considering a structured medication review to find medicines that may raise their risk of falling. For psychotropic medicines, it recommends reviewing them, discussing the falls risk with the person and planning withdrawal as appropriate.

How do we find patients with polypharmacy?

NHSBSA's polypharmacy prescribing comparators on ePACT2 show how many patients in each practice and PCN are on 8, 10, 15 or 20 or more medicines, and flag risky combinations such as several analgesics at once.

Sources

  1. Understanding polypharmacy, overprescribing and deprescribing (Specialist Pharmacy Service)
  2. Government pledges to reduce overprescribing of medicines, 22 September 2021 (GOV.UK)
  3. Primary and community healthcare support for people living with frailty, press release, 5 December 2025 (National Audit Office)
  4. Network Contract DES 2026/27, Part A guidance: clinical and support services (section 8), 9 November 2026 (NHS England)
  5. Medicines optimisation: polypharmacy prescribing comparators (NHSBSA)
  6. Falls: assessment and prevention in older people and in people 50 and over at higher risk, NICE guideline NG249, recommendations
  7. Medicines optimisation, NICE guideline NG5, recommendations
  8. Network Contract DES: contract specification 2026/27, section 7, Additional Roles Reimbursement Scheme (NHS England)

More guides

All guides